Can resistance enhance selection of treatment? (CREST)

Phase 4

Completed

• Conditions: HIV infection; Infection - Acquired immune deficiency syndrome (AIDS / HIV)

• Registration Number: ACTRN12605000781640
• Lead Sponsor: ational Centre in HIV Epidemiology and Clinical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-12-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

HIV infected patients taking combination antiretroviral therapy, with plasma HIV RNA> 2000copies/mL, who were willing to change ARVs and who provided informed.

Exclusion Criteria

Patients who were ARV naive, who were experiencing an acute illness or judged to be unable to comply with the protocol requirements.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The comparison between randomly assigned study arms in the mean area under the curve plasma HIV RNA [At 48 weeks]

Secondary Outcome Measures

Name	Time	Method
Proportion of patients with undetectable plasma HIV RNA [At 48 weeks.];Changes in CD4+ cell count[Up to 48 weeks];Use of resistance test result in selecting new ART regimen.[At baseline.]